To this aim, Pax5+/− mice are transiently treated with ruxolitinib, a JAK1/2 inhibitor that preferentially targeted Pax5+/− versus wild-type B-cell progenitors and leads to B-ALL prevention [35]. The gene discussed is PAX5; the disease is precursor B-cell acute lymphoblastic leukemia.